De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.

British Journal of Haematology
Olfat IsmaelSeiji Kojima

Abstract

Myelodysplastic/myeloproliferative uclassifiable (MDS/MPN-U) is a rare myeloid neoplasm characterized by myelodysplasia and myeloproliferation at the time of initial presentation, which is usually a diagnosis of exclusion. The molecular pathogenesis of MDS/MPN-U patients remains to be elucidated. Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one carried somatic mosaicism of RUNX1 mutation with JAK2(V617F) mutation and one had dual RUNX1 and FLT3-internal tandem duplication mutations with progression to acute myeloid leukaemia (AML). Germline mutation of TP53 was detected as a sole genetic lesion in one patient. JAK2(V617F) and somatic mosaicism of KRAS and TET2 mutations co-existed in one patient. Otherwise, no alterations were detected in PTPN11, NRAS, CBL and ASXL1 genes. ETV6-PDGFRB fusion transcript was not detected in all patients. Four patients recieved haematopoietic stem cell transplantation (HSCT); three patients relapsed and one achieved complete remission after three donor lymphocyte infusions. Our findings suggest that the mutational spectrum observed in childhood MDS/MPN-U is quite different from that seen in juvenile myelomonocytic leukaemia and, to some extent, r...Continue Reading

References

Sep 7, 2007·Journal of Pediatric Hematology/oncology·Akira ShimadaYasuhide Hayashi
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Oct 3, 2009·Haematologica·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Dec 10, 2009·Haematologica·Andreas ReiterMario Cazzola
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clara RicciFrancesco Onida
Apr 23, 2010·British Journal of Haematology·Yuka SugimotoJaroslaw P Maciejewski
Jul 6, 2010·Nature Genetics·Thomas ErnstNicholas C P Cross
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KohlmannTorsten Haferlach
Mar 16, 2011·British Journal of Haematology·Ulrike BacherNicolaus Kröger
Dec 14, 2011·Hematology·Mario CazzolaRosangela Invernizzi
Dec 27, 2011·Seminars in Diagnostic Pathology·Elizabeth Hyjek, James W Vardiman

❮ Previous
Next ❯

Citations

Sep 29, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Meng-Ju LiDong-Tsamn Lin
Feb 10, 2017·Blood·Raman SoodPaul Liu
Jun 24, 2017·Nature Reviews. Cancer·Michael W N DeiningerEric Solary

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.